A subset of high-titer anti–factor VIII A2 domain antibodies is responsive to treatment with factor VIII-Reference-Cited by-同舟云学术

A subset of high-titer anti–factor VIII A2 domain antibodies is responsive to treatment with factor VIII

Published:2016-04-21 Issue:16 Volume:127 Page:2028-2034
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Eubanks Joshua¹,Baldwin W. Hunter²,Markovitz Rebecca¹,Parker Ernest T.²,Cox Courtney²,Kempton Christine L.²³,Meeks Shannon L.²^ORCID

Affiliation:

1. School of Medicine, Emory University, Atlanta, GA;

2. Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta/Emory University, Atlanta, GA; and

3. Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA

Abstract

Key Points Discrepancies exist between inhibitor titer and bleeding phenotype in anti-fVIII antibodies. A subset of high-titer type 2 anti-A2 inhibitors can be treated with fVIII.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/16/2028/1393024/2028.pdf

Reference31 articles.

1. The A2 subunit of factor VIIIa modulates the active site of factor IXa.;Fay;J Biol Chem,1998

2. Contribution of factor VIIIa A2 and A3-C1-C2 subunits to the affinity for factor IXa in factor Xase.;Jenkins;Biochemistry,2004

3. Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog.;Lollar;J Biol Chem,1991

4. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies.;Prescott;Blood,1997

5. Inactivation of factor VIII coagulant activity by two different types of human antibodies.;Gawryl;Blood,1982

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factor VIII antibody immune complexes modulate the humoral response to factor VIII in an epitope-dependent manner;Frontiers in Immunology;2023-08-31

2. Impact of different factor VIII inhibitor kinetic profiles on the inhibitor titer quantification using the modified Nijmegen–Bethesda assay;Research and Practice in Thrombosis and Haemostasis;2022-11

3. Structural insights into blood coagulation factor VIII: Procoagulant complexes, membrane binding, and antibody inhibition;Journal of Thrombosis and Haemostasis;2022-09

4. Inhibitors: Diagnostic challenges, unknowns of inhibitor development, treatment of bleeding and surgery, and insights into diagnosis and treatment in China;Haemophilia;2022-05

5. Removal of single‐site N‐linked glycans on factor VIII alters binding of domain‐specific monoclonal antibodies;Journal of Thrombosis and Haemostasis;2021-12-17